Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates

Yongjun Cheng¹, Jinhua Zhao¹, Wenli Qiao¹, Kai Chen²

¹Department of Nuclear Medicine, The First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, P.R. China; ²Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Received June 24, 2014; Accepted July 4, 2014; Epub August 15, 2014; Published August 30, 2014

Abstract: Malignant gliomas, especially glioblastoma multiforme, are the most widely distributed and deadliest brain tumors because of their resistance to surgical and medical treatment. Research of glioma-specific bioconjugates for diagnosis and therapy developed rapidly during the past several years. Many studies have demonstrated that chlorotoxin (CTX) and Buthus martensii Karsch chlorotoxin (BmK CT) specifically inhibited glioma cells growth and metastasis, and accelerated tumor apoptosis. The bioconjugates of CTX or BmK CT with other molecules have played an increasing role in diagnostic imaging and treatment of gliomas. To date, CTX-based bioconjugates have achieved great success in phase I/II clinical trials about safety profiles. Here, we will provide a review on the important role of ion channels in the underlying mechanisms of gliomas invasive growth and how CTX suppresses gliomas proliferation and migration. We will summarize the recent advances in the applications of CTX bioconjugates for gliomas diagnosis and treatment. In addition, we will review recent studies on BmK CT bioconjugates and compare their efficacies with CTX derivatives. Finally, we will address advantages and challenges in the use of CTX or BmK CT bioconjugates as specific agents for theranostic applications in gliomas.

Keywords: Chlorotoxin (CTX), Buthus martensii Karsch chlorotoxin (BmK CT), glioma, imaging, therapy

Introduction

Gliomas, including glioblastoma multiforme (GBM), astrocytoma, anaplastic astrocytoma, and oligodendroglioma, are the most lethal types of primary brain tumors. However, effective treatment of gliomas clinically remains a big challenge [1]. Though survival rates of patients can be improved by complete surgical resection of tumor, it is very difficult for neurosurgeon to accurately locate and distinguish neoplastic tissue from healthy nervous tissue [2]. In addition, gliomas are resistant to chemotherapy and radiation for their special nature of infiltrating proliferation pattern with rapid growth rate and highly invasive ability [3, 4]. Therefore, it is urgently needed to find a more effective therapeutic approach against this malignant disease. In recent years, scorpion toxins such as chlorotoxin (CTX) and the chlorotoxin-like toxin derived from Buthus martensii Karsch (BmK CT) have been explored as candidates for glioma diagnosis and therapy.

CTX was purified from the giant yellow Israeli scorpion Leiurus quinquestriatus venom in 1993. It contains 36-amino-acid residues including four disulfide bonds (amino acid sequence: MCMPCTTDTD QMARKCDCCGGK GRGKCYGPQ CLCR [5]. Previous studies have shown that a matrix metalloproteinase-2 (MMP-2) receptor-associated chloride channel and a glioma-specific chloride channel (GCC) are specifically expressed in the membranes of glioma cells but not in normal human cell membranes. CTX blocks the GCC and specifically binds to MMP-2 receptor. Upon binding of CTX, the MMP-2 complex and GCC are internalized into the cell membrane lipid rafts, leading to inhibition of glioma cell migration and invasion. Up to date, CTX has passed preclinical safety test and entered a phase I clinical trial.

BmK CT is a peptide with 35 amino acids and four disulfide bonds, sharing approximately 68% amino acid homology with CTX. After the purification from the Chinese scorpion Buthus
Martensii Karsch venom, BmK CT demonstrated an ability of inhibiting glioma cells invasion and migration. Previous research suggests BmK CT selectively interacts with MMP-2 receptor and blocks the GCC in a mechanism similar to that of CTX. Indeed, CTX and BmK CT have been widely studied on glioma cells. The peptides have been demonstrated their glioma specificities in a variety of formats, including radiolabeled, fluorescent, and nanoparticle-based derivatives.

While some available reviews focus on the application of CTX-based agents for either imaging [6] or therapy [7], we believe this review is unique, which summarizes the recent progress on the development of CTX and BmK CT bioconjugates for theranostic applications in gliomas.

The role of ion channels in gliomas

Recent molecular biology studies have found that malfunctions of ion channels on cell membranes are associated with gliomas [8, 9]. For example, intracellular Ca\(^{2+}\) is a main regulator for cell motility owing to Ca\(^{2+}\)-activated K\(^+\) channel (KCa3.1) elevates glioma migration. The data revealed a notable decrease in tumor invasion into around brain in vivo by ablating KCa3.1 with inducible siRNA. In addition, chloride channel (ClC) protein family, which contains nine members [12], namely ClC-Ka, ClC-Kb and ClC-1 through ClC-7, was absent in normal brain tissue, but abundantly expressed in glioma cell lines. Among them, ClC-3, in particular, has been suggested to affect the invasion and migration of glioma cells by contributing to the efflux of chloride ions and the associated obligatory movement of water [13]. ClC-3 forms protein complexes with membrane type-I MMP, MMP-2, tissue inhibitor of metalloprotein-2, and \(\alpha_\beta_5\) integrin, co-localizing with Ca\(^{2+}\)-activated K\(^+\) channel to lipid raft domain of invadopodia. Furthermore, compared with normal tissues, chloride intracellular channel 1 (CLIC1), a non-classical ion channel protein, has been shown to be overexpressed in gliomas [14]. The data suggested that CLIC1 involved in the mechanism of glioma development through the association with cell cycle and functional expression during oxidative stress conditions [15]. Setti et al. demonstrated that CLIC1 is essential for self-renewal and proliferation of GBM cancer stem cells [16].

The initial findings on the effects of CTX on chloride ion channels suggested that a glioma-specific chloride channel facilitates shape changes during glioma cell migration and invasion [17]. However, additional experiments showed that submicromolar concentrations of chlorotoxin cannot block volume-regulated, Ca\(^{2+}\)-activated and cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels, suggesting CTX cannot be classified as a general chloride channel toxin [18]. Although the molecular mechanism of CTX in glioma remains elusive, there is a general agreement that CTX binds specifically to the ClC-3/MMP-2 membrane complex [7], which may cause endocytosis of ClC-3/MMP-2 and a reduction of glioma invasiveness.

Progress of CTX-related basic science and applications

CTX and CTX-like peptides

CTX can be prepared through chemical synthesis and subsequent oxidative folding, but the final yield of this process is usually insufficient [19]. Therefore, Wang et al. provided an efficient approach for the preparation of active CTX and its analogs through the recombinant expression of designed CTX precursors in Escherichia coli (E. coli) and subsequent in vitro enzymatic and oxidative refolding [20]. The designed CTX precursors were expressed in E. coli, which reformed by a glutathione transferase (GST)-tag and a 6xHis-tag. Subsequent to the removal of the Nterminal tag, the sulfonated CTX can be refolded with ~80% yield under optimized conditions.

TM-601 was purified from the naturally occurring peptide CTX using solid-phase chemical synthesis method. TM-601 shares physical and biologic properties with natural CTX, and it has been approved by the US Food and Drug Administration for clinical studies. In 2010, Kesavan et al. identified annexin A2 as a new targeting molecule for TM-601 in human umbilical vein endothelial cell and multiple human tumor cell lines [21]. They demonstrated that TM-601 bound to the surface of Panc-1 cells depending on the level of annexin A2 expression. Annexin A2 plays an important role in
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

angiogenesis by regulating plasminogen activation and binding to tissue plasminogen activator on vascular endothelial cells. Since TM-601 also binds MT1-MMP and annexin A2 is overexpressed intracellularly in all cells, the molecular mechanism of TM-601 specificity toward cancers remains unclear. Jacoby et al. found that TM-601 not only binds a wide range of tumor cell types but also can be internalized by proliferating human vascular endothelial cells [19]. The study demonstrated an anti-angiogenic effect of TM-601 using both the chicken chorioallantoic membrane assays and the mouse Matrigel plug assays. Wiranowska et al. discovered that TM-601 localizes near trans-Golgi in glioma, lung carcinoma, and normal vascular endothelial cells, while it is dispersed in the cytoplasm in astrocytes and normal human dermal fibroblasts (NHDF) [22]. The uptake of TM-601 by U373 glioma cells is rapid and dependent on time and concentration. Chlorpromazine, a kind of clathrin-dependent intracellular transport of coated pits, can induce intracellular accumulation of the drug and clathrin near the Golgi; however, suppressers like amiloride (non-selective macropinocytosis) and filipin (caveola-dependent endocytosis) lack this function. On the contrary, amiloride remarkably affected TM-601 uptake in NHDF cells, suggesting that macropinocytosis is the decisive uptake route of TM-601 in these cells.

Recently, a novel CTX-like peptide, namely AaCtx, was purified from the venom of the scorpion Androctonus australis. It has a 70% similarity with CTX in terms of amino acid sequence. Invasion and migration of human glioma cells can be both inhibited by native and synthetic AaCtx; however, while the inhibition activity of AaCtx was lower than that of CTX [23]. Nevertheless, the advance of novel CTX homologous peptides may offer an approach to achieve multiple-point mutations in the structure of CTX, leading to valuable information regarding the molecular mechanism of CTX.

Putative mechanism of gliomas invasion and metastasis suppressed by CTX

CTX has been demonstrated its capability to selectively and specifically act on MMP-2, but not on MMP-9, -3, and -1, which are also overexpressed in glioma cells. CTX can decrease the cell membrane expression of MMP-2 by inhibiting the MMP-2 enzyme activity. Recent studies suggested that CTX prevents cell shrinkage, thereby reducing the invasion ability of glioma cells through compact extracellular space in normal brain [24]. By decreasing MMP-2 activity, CTX prevents proteolytic degradation of ECM and the subsequent release of glioma cells from the constraints of cellular interactions with ECM.

Recently, the expression of CICs and MMP-2 was studied in two human glioma cell lines (STTG1 and U251MG). A CIC-3 inhibitor (CTX), a non-specific CIC inhibitor (5-nitro-2,3-phenylpropylamino benzoic acid (NPPB)), and CIC-3 siRNA knockdown were used to study the inhibition effects of CIC [25]. Glioma cell invasion was remarkably but not completely inhibited by CIC-3 and MMP-2 siRNA knockdown, and by CTX treatment. Addition of CTX to siRNA-treated glioma cells only slightly increased the suppression of invasion. In contrast, the non-specific CIC blocker NPPB completely blocked the cell invasion, indicating that CICs are crucial in glioma cell migration and invasion. This study demonstrated that CIC-3 is the primary CIC associated with invasiveness; however, pharmacological blockade of CIC-3 alone is not sufficient to inhibit glioma cell invasion. Therefore, future therapy for gliomas may increase the likelihood of success by aiming at pharmacologic blockade targeting multiple CICs, as well as diminishing Ca\(^{2+}\)/calmodulin-dependent protein kinase II and CIC-3 activities.

Application of CTX bioconjugates for gliomas imaging and therapy

CTX exhibits several advantages as a ligand for diagnosis and treatment of tumors as compared with the widely used antibodies. Firstly, it is a small peptide with compact structure consisting of an α-helix and a simple three-stranded antiparallel β-sheet. Secondly, it can penetrate the blood-brain barrier (BBB) due to its compact structure [26]. Furthermore, CTX interacts with the MMP-2 receptor to inhibit glioma metastasis and invasion [5]. However, the size of CTX bioconjugates coupled with imaging moiety or therapeutic agent may be significantly different as compared to that of CTX. Therefore, the BBB penetration property of newly developed CTX bioconjugates needs to be carefully studied.

Up to date, the CTX bioconjugates have played increasingly critical roles in diagnostic imaging
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

**Table 1.** Representative CTX bioconjugates in the applications of glioma diagnosis and treatment

<table>
<thead>
<tr>
<th>Type</th>
<th>Cell Line</th>
<th>Study</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imaging</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cy5.5-CTX</td>
<td>9L</td>
<td>In vitro &amp; In vivo</td>
<td>[30]</td>
</tr>
<tr>
<td>Cy5.5-CTX (Modified)</td>
<td>ND2:SmoA1</td>
<td>In vivo</td>
<td>[31]</td>
</tr>
<tr>
<td>BLZ-100</td>
<td>LN229</td>
<td>In vivo</td>
<td>[32]</td>
</tr>
<tr>
<td>IRDye 800CW-CTX</td>
<td>ND2:SmoA1, HTB-186, U87MG, A549, 22Rv1</td>
<td>In vivo</td>
<td>[33]</td>
</tr>
<tr>
<td>Gd-DTPA-CTX</td>
<td>HEK293, C6, Bel-7402</td>
<td>In vitro &amp; In vivo</td>
<td>[48]</td>
</tr>
<tr>
<td><strong>Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>131I/125I-CTX</td>
<td>D54MG</td>
<td>In vivo</td>
<td>[58]</td>
</tr>
<tr>
<td>CTX-Fcs</td>
<td>PANC-1</td>
<td>In vitro</td>
<td>[56]</td>
</tr>
<tr>
<td></td>
<td>A172</td>
<td>In vitro</td>
<td>[63]</td>
</tr>
<tr>
<td>NO-CTX</td>
<td>T98G, U87MG, NHAs, HBMECs</td>
<td>In vitro</td>
<td>[66]</td>
</tr>
<tr>
<td></td>
<td>T98G, U87MG, NHAs, HBMECs</td>
<td>In vitro</td>
<td>[67]</td>
</tr>
<tr>
<td><strong>Imaging and Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX-LS/DOX-LS/DiR-LS</td>
<td>C6, U87MG, U251MG</td>
<td>In vitro &amp; In vivo</td>
<td>[40]</td>
</tr>
<tr>
<td>PAMAM-PEG-CTX/DNA</td>
<td>C6, HEK293</td>
<td>In vitro &amp; In vivo</td>
<td>[74]</td>
</tr>
</tbody>
</table>

Notes: D54MG, U87MG, U251MG, T98G, and LN229 are human glioblastoma cell lines; NHAs, normal human astrocytes; HBMECs, human brain microvascular endothelial cells; 9L and C6 are rat glioma cell lines; PANC-1, human pancreatic carcinoma cell line; A172, human glioma cell line; HEK293T and HEK293 are human embryonic kidney cell lines; ND2:SmoA1 is a transgenic mouse model of glioma; HTB-186, medulloblastoma cell line; A549, lung carcinoma cell line; 22Rv1, prostate carcinoma cell line; Bel-7402, human hepatocellular carcinoma cell line.

**Table 2.** Representative CTX-based nanoparticles in the applications of glioma diagnosis and treatment

<table>
<thead>
<tr>
<th>Type</th>
<th>Cell Line</th>
<th>Study</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imaging</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG iron oxide-CTX</td>
<td>9L</td>
<td>In vitro &amp; In vivo</td>
<td>[36]</td>
</tr>
<tr>
<td>PEG iron oxide-CTX-Cy5.5</td>
<td>ND2:SmoA1</td>
<td>In vitro &amp; In vivo</td>
<td>[37]</td>
</tr>
<tr>
<td>PEI-NaYF(4): Yb, Er/Ce-CTX</td>
<td>C6</td>
<td>In vitro</td>
<td>[39]</td>
</tr>
<tr>
<td><strong>Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron oxide-PEG-CTX</td>
<td>C6</td>
<td>In vitro</td>
<td>[25]</td>
</tr>
<tr>
<td>Ag/Al@PNPs-CTX</td>
<td>U87MG</td>
<td>In vitro &amp; In vivo</td>
<td>[56]</td>
</tr>
<tr>
<td>PBdot-CTX</td>
<td>ND2:SmoA1</td>
<td>In vivo</td>
<td>[44]</td>
</tr>
<tr>
<td><strong>Gene Delivery and Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEI-PEG-CTX/DNA</td>
<td>C6, DA0Y, NIH3T3</td>
<td>In vitro</td>
<td>[38]</td>
</tr>
<tr>
<td>SNALPs-CTX/asOs, SNALPs-CTX/siRNA</td>
<td>U87MG, GL261, HEK293T</td>
<td>In vitro &amp; In vivo</td>
<td>[41]</td>
</tr>
<tr>
<td>Iron oxide-PEG-PEI-CTX/DNA</td>
<td>C6</td>
<td>In vivo</td>
<td>[75]</td>
</tr>
<tr>
<td>Iron oxide-PEG-PEI-CTX/siRNA</td>
<td>C6</td>
<td>In vivo</td>
<td>[77]</td>
</tr>
<tr>
<td>Iron oxide-PEIb-CTX/siRNA</td>
<td>C6</td>
<td>In vivo</td>
<td>[78]</td>
</tr>
<tr>
<td>Iron oxide-PEG-MTX-CTX</td>
<td>rCM, 9L, D283</td>
<td>In vitro &amp; In vivo</td>
<td>[82]</td>
</tr>
<tr>
<td>Iron oxide-PEG-CTX, iron oxide-PEG-RGD</td>
<td>U87MG, MCF-7, 9L</td>
<td>In vitro &amp; In vivo</td>
<td>[46]</td>
</tr>
</tbody>
</table>

Notes: DA0Y, medulloblastoma tumor cell line; NIH3T3, mouse fibroblast cell line; rCM, rat cardiomyocytes; GL261, mouse glioma cell line; D283, human medulloblastoma cell line; MCF-7, human breast adenocarcinoma cell line.

and treatment of gliomas [27]. CTX can be complexed with a variety of moieties, including radioactive iodine isotopes, fluorescent molecules, nanoparticles (NPs), chemotherapy drugs, germ plasm, liposomes, immunogenic molecules and nitric oxide. The bioconjugates containing more than two components of the above elements are listed in Tables 1 and 2.
Diagnostic imaging with CTX bioconjugates

Radioiodinated CTX

CTX has been radiolabeled with $^{125}$I or $^{131}$I to afford the complexes, such as $^{125}$I-CTX or $^{131}$I-CTX [27]. The characteristic radiation released from these decayed radionuclides have been subsequently detected and recorded by using SPECT and a gamma camera to accurately qualify, quantify, and localize the brain tumor tissues and cells. At 24 hours after the injection of $^{131}$I-CTX, brain tumor-to-muscle ratio of accumulated radioactivity can reach to 39.13 ± 4.6 [28]. Up to date, $^{131}$I-TM-601 has been the most extensively studied complex of CTX in humans. $^{131}$I-TM-601 was shown to be safe to administer in patients with gliomas, and it can be used as a SPECT imaging agent for evaluating primary tumor extent in phase I/II clinical trials [29]. Further modification of $^{131}$I-TM-601 with isotopes that have better imaging capabilities may provide an important imaging tool for determining the extent of glioma growth.

Fluorescent dye conjugated CTX

In order to provide real-time biological information to distinctly excise small foci of cancer cells and tumor margins, Veiseh et al. conjugated CTX to a fluorescent dye (Cy5.5) to produce the complex of Cy5.5-CTX [30]. The specific binding of Cy5.5-CTX with tumor cells can be detected with light microscopy. A novel monolabeled peptide containing a single near infrared fluorescent (NIRF) molecule was reported by Akcan et al. [31]. Substitution of Lys15 and Lys23 with either alanine or arginine retained the functional efficacy of CTX, while Lys27 can be specifically labeled with Cy5.5 (Figure 1). In another example, tumor paint BLZ-100, an indocyanine green (ICG)-CTX conjugate, was developed for an optimized NIR imaging system. By using a normal charge-coupled device (CCD) camera, Butte et al. reported a small, sensitive, and inexpensive NIR imaging system [32].

IRDye 800CW is a dye designed to limit interfering autofluorescence and exploit the enhanced permeability. It can ensure optimum signal view at deeper tissue with high signal-to-background ratios. In addition, operational imaging instruments, such as the Leica FL800 and Zeiss Pentero microscope, are compatible with IRDye 800CW. IRDye 800CW-CTX has been developed as a targeted imaging agent for brain tumors in ND2:SmoA1 model [33]. The targeting specificity of IRDye 800CW-CTX was evaluated using A549 (lung carcinoma), U87MG (glioblastoma), HTB-186 (medulloblastoma), and 22Rv1 (prostate carcinoma) cell lines. The results showed that IRDye 800CW-CTX binds to tumor cells specifically. Interestingly, blocking IRDye 800CW-CTX binding at room temperature was unsuccessful; however, blocking was observed at 4°C, a temperature at which inter-
nalization is slower. The fluorescence signal was reduced approximately 75% when A549 cells were pretreated with the MMP-2 inhibitor 1,10-phenanthroline at a dose (200 µM) that successfully inhibits glioma cell invasion. Individual tumor-bearing animals were injected with IRDye 800CW-CTX. Evan’s Blue perfusion was used to measure the integrity of the BBB. The extravasation of Evan’s Blue located only in fields of tumors but not anywhere else in the brain sections or whole brain, suggesting that the BBB permeability can be altered by the presence of the tumors.

**CTX-conjugated nanoparticles**

Novel tools for the diagnosis of gliomas have been developed based on CTX-containing nanoparticles [34, 35]. For example, CTX-based superparamagnetic iron oxide nanoparticles (NPs) have been reported [36]. The nanoparticles could bind to glioma cells specifically, and be used as a contrast agent for MRI to enhance the differentiation of the tumor from normal brain tissue. Later on, a dual modality optical/MR imaging nanoprobe was developed from the same group. Iron oxide NPs were used as the probe core, which was coated with biocompatible PEG-chitosan in the form of nanoparticle copolymer covalently conjugated with CTX and Cy5.5 [37]. The probe could label the tumor in genetically engineered mice, and be dually detected by optical imaging and MRI. The NPs were proved to be nontoxic, permeable through the BBB, and the tumor uptake of fluorescent NPs can be clearly visualized even at 120 h postinjection for optical imaging. Recently, the group reported a nonviral nanovector system P-PEG-AF-CTX comprising a fluorescent dye Alexa Fluor 647 (AF), polyethylenimine (PEI) polymer, PEG, and CTX [38]. The results demonstrated that the nanovector could be effectively loaded with genes for the specific labeling and genetic transfection of tumor cells. To date, CTX-functionalized iron oxide NPs have been extensively applied for imaging brain tumors by optical imaging and MRI [36, 37, 39]. The nanosystems are typically consisted of PEG, chitosan co-polymers, fluorescent dyes, targeting molecules, and an iron oxide core.

The CTX-modified liposomes have been recently developed for glioma imaging and therapy.
The optical imaging results showed that CTX-modified DiR-loaded liposomes can accumulate in the subcutaneous and intracranial glioma tumors (Figures 2 and 3). The U87MG cells bearing armpit tumor model revealed that CTX-modified doxorubicin (DOX)-loaded liposomes can inhibit tumor growth effectively. Overall, the results demonstrated that the CTX-modified liposome was a promising delivery system which could enhance the intracellular uptake of imaging agents or anticancer drugs.

In another example, Costa et al. covalently combined CTX with liposomes which encapsulated small interfering RNAs (siRNAs) or antisense oligo-nucleotides (asOs) [41]. The data demonstrated that CTX coupled stable nucleic acid lipid particles (SNALPs) can be successfully applied for in vivo studies, and CTX-SNALPs exhibited excellent physicochemical properties, including electrical neutrality, low size, high protection against enzymatic degradation, and high encapsulation efficiency. Cellular association and internalization studies demonstrated that the CTX-SNALPs could stimulate particle internalization in glioma cells as compared to normal cells.

A new class of fluorescent probes, named semiconducting polymer dots (Pdots), has been applied in fluorescent-based tumor imaging [42, 43]. As compared to quantum dots (Qdots), Pdot probes are small and extremely bright, making them attractive for serving as targeted imaging agents. Differing from Qdots, Pdots are made from highly biocompatible and non-toxic materials, rendering them an appealing candidate as a fluorescent imaging probe for clinical applications. Recently, polymer-blend dots (PBdots) were developed by using an efficient deep-red emitting polymer as the acceptor and a visible-light harvesting polymer as the donor. Wu et al. demonstrated the PBdot-CTX conjugate was able to permeate the BBB and specifically target tumor tissue in a transgenic mouse model (ND2:SmoA1) [44]. The probe with 15 nm in average size was resistant to photo-bleaching, 15 times brighter than Qdots, and stable in serum for over 72 h.

Integrin \( \alpha_\beta_3 \) and MMP-2 play significant roles in neural tumor cell invasion and angiogenesis [45]. Fang et al. used biocompatible polymer-coated iron oxide to conjugate CTX or arginine-glycine-aspartic acid (RGD) on the surface to...
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

develop and assess two tumor-specific nanoprobe’s that target MMP-2 and \(\alpha_\beta_3\) integrin [46]. In this study, both nanoprobe’s presented long-term stability and excellent dispersion in cell culture media. NP-CTX diffused throughout the tumor, while NP-RGD showed high accumulation near the blood vessels. The results demonstrated that both NP-CTX and NP-RGD were target-specific to integrin MMP-2 and \(\alpha_\beta_3\). Compared to receptor-negative cell lines, both NP-CTX and NP-RGD exhibited enhanced cellular uptakes in receptor-positive cell lines. In vivo MRI results showed that nanoprobe’s provided contrast enhancement in the U87MG xenograft mouse model, and both NP-CTX and NP-RGD preferentially accumulated in U87MG tumors. In terms of \(R_1\), a contrast enhancement was observed for NP-RGD (11.939 ± 2.746 s\(^{-1}\)) and NP-CTX (5.181 ± 1.567 s\(^{-1}\)) in the tumors at 4 h post-injection, which is significantly higher than that for NP-SIA (as control) (0.617 ± 1.447 s\(^{-1}\)).

Rare-earth metals, exhibiting unique features for optical imaging, have recently been applied to tumor imaging. These nanoprobe’s are soluble in aqueous solutions, fluorescent and stable over a long period of time [34]. After functionalized with CTX, small polyethyleneimine nanoprobe’s coated with hexagonal-phase NaYF\(_4\):Yb, Er/Ce were used to image C6 glioma xenografted tumors in vivo [47]. There was no perceptible indication of toxicity observed for the CTX:NPs. Significant upconversion fluorescence was observed in the xenograft tumors of the CTX:NPs-injected Balb-c nude mice, whereas no obvious fluorescence signal was observed in the tumors of the NPs-injected Balb-c nude mice, proving the specificity of the CTX:NPs for targeting xenograft gliomas.

Contrast agents are great helpful for clinical diagnosis of tumors using MRI, particularly for brain tumors at an early stage. However, the contrast agents in low molecular weight which are commonly used at present, such as gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA), have several disadvantages, such as non-specificity, low contrast efficiency, and rapid renal clearance. A recent study showed that a macromolecular MRI contrast agent based on dendrigraft poly-L-lysines can be successfully synthesized by using CTX-modified conjugate as the main scaffold and Gd-DTPA as the payload [48]. Fluorescence microscopy results revealed that the modification of CTX could significantly boost the cellular ingestion in liver tumor cell and C6 glioma cell lines, but not in normal cell line. The MRI signal of mice treated with CTX-modified contrast was enhanced, which was remarkably higher than that of commercial control and unmodified conjugate. The signal improvement of CTX-modified contrast agent retained much longer in circulation than that of controls, which could be helpful for more accurate diagnosis of tumors. Taken together, CTX-modified dendrimer-based conjugate might be effective as a MRI contrast agent for accurate diagnosis of gliomas.

**Targeted therapy with CTX bioconjugates**

The success of targeted cancer therapy largely depends upon receptor-mediated ligand binding selectively to tumor cells. This method needs high selectivity or specificity of ligand targeting tumor cells or other tumor related cells, such as blood vessels. The key of success is that receptors over-express uniquely by tumor cells, but minimally by normal brain tissues. A lot of targeting molecules have been assessed containing epidermal growth factor receptor antibodies [49], CTX, transferring [50], F3 homingpeptide [51], insulin receptor [52], cationic albumin [53], and methotrexate [54]. The basic strategy is to identify a cellular toxin, modify the toxin to maximize antitumoral activity, and deliver the toxin directly to the tumor with a tumor-specific ligand acting as a carrier molecule. Among these identified targeting ligands so far, CTX has been recognized as an appropriate agent for its capability to specifically target a great number of cancers like brain tumors, breast and pancreatic cancers [55-57].

**Radiolabeled CTX**

\(^{125}\)I- or \(^{131}\)I-labeled CTX was the first complex used in vivo targeting and biodistribution experiments, and the radiolabeled-CTX has been used in post-operative therapy [28]. Shen et al. evaluated radiation doses of \(^{131}\)I-CTX in human glioma xenografted model using athymic nude mice, and suggested that projected radiation doses in patients receiving 370 MBq of \(^{131}\)I-CTX [58]. In addition, Shirimardi et al. showed that \(^{131}\)I-CTX was stable in PBS solution and human serum [59]. Compared with the concentration of radioactivity in the liver, kidneys, stomach, and intestine, the blood clearance of \(^{131}\)I-CTX was moderate.
A phase I study of $^{131}$I-TM-601 has been finished to assess the safety, biodistribution, dosimetry and tolerability, in adult patients who suffer from recurrent high-grade glioma [60]. During the follow-up period, there were no grade III or IV toxicities associated with the therapeutic agent or the method of administration. A phase II study was then carried out to assess the safety and efficacy of multiple doses of radiolabeled TM-601. Improved survival and unnoticeable toxicity were found for patients receiving 6 versus 3 doses of $^{131}$I-TM-601 [61].

**CTX-fused immunogenetic molecules**

IgG antibodies play an important role in humoral immunity. They have been considered as pro-inflammatory mediators for a long time. The functions and specificities of antibodies are determined by the Fc (crystallizable) domain. Studies from Anthony et al. demonstrated that the sialylated IgG Fcs can affect in vivo activity of intravenous immunoglobulin [62]. Kasai et al. developed two forms of bioconjugate, which were human IgG-Fcs with/without a hinge region fused to CTX [63]. CTX combined to IgG-Fcs was operated as a monomer of 30 kDa without a hinge region (M-CTX-Fc) and a dimer of 60 kDa with a hinge region (D-CTX-Fc). The monomeric and dimeric CTXs inhibited human glioma A172 cell growth. Interestingly, the dimer showed a less inhibitory activity than the monomer, indicating M-CTX-Fc may be more suitable than D-CTX-Fc as a drug delivery system targeting to MMP-2. Recently, the same group has identified the inhibitory mechanism of M-CTX-Fc on MMP-2 in PANC-1 cells, the human cell line derived from pancreatic carcinoma [56]. The results suggested that the M-CTX-Fc fusion protein might be a promising agent for MMP-2 targeted treatment.

**CTX-NO therapy**

Nitric oxide (NO) is a small molecule which has been discovered to play multiple roles within the human body, including the maintenance of the tuned balance between tumor suppression and progression [64]. Due to the short half-life of NO, nitric oxide donors are utilized to release NO in order to prolong periods for therapeutic purposes. The study demonstrated that non-specific NO donors induced chemosensitivity in glioma cells by releasing NO [65]; however, the therapeutic efficacy requires high doses of NO to be delivered into tissues surrounding the tumor site. For instance, Safdar et al. reported that CTX can react with NO gas to provide a NO-releasing compound (CTX-NO), while retaining its capability to preferentially target glioma cells [66]. CTX-NO led to tumor cell death in a dose-dependent way, while normal cell viability was only affected at high NO concentrations. Later on, the same group studied a targeted NO donor as a pre-therapy to enhance the sensitivity of chemotherapy in glioma cells [67]. Their results demonstrated that CTX-NO can improve the therapeutic potential used in conjunction with carmustine (BCNU) or temozolomide (TMZ). CTX-NO was capable of reducing p53 expression in U87MG and T98G cells alone, or combined with chemotherapy. The NO released by CTX-NO led to unnoticeable alteration in the chemo-sensitivity of normal control cells. The pretreatment with CTX-NO remarkably decreased the expression of O$^6$-methylguanine-DNA methyltransferase (MGMT) in glioma cells. MGMT is a 22 kDa protein repairing alkylation at the O$^6$ position of guanine on DNA strands [68, 69]. Compared with the study of NO alone, the combination of NO and TMZ had minimal effect on p53 expressions in T98G glioma cells. However, the combination of BCNU and NO induced noticeable decrease in p53 expressing levels. The data suggested that the activity of p53 may play a crucial role in determining cellular response and maintaining the integrity of the genome, either inducing apoptosis after being exposed to harmful stimuli such as chemotherapy and radiation, or activating DNA repair mechanisms [70]. Remarkable inhibition in cell invasion could be observed under the condition where chemotherapy was coupled with CTX-NO. The cell invasion was reduced by 54.3 ± 6.1% and 70.5 ± 8.6% using NO in conjunction with BCNU and the combination of NO and BCNU, respectively.

**CTX combined with gene therapy**

Gene therapy could enhance the dismal prognosis of patients suffering from glioma [71]. However, the degradation of nucleic acids by nucleases and the presence of the BBB restricting entry of therapeutic molecules into the brain, are main challenges for delivering nucleic acids in vivo [72, 73]. Therefore, it is critical that oligonucleotides are appropriately transported by vehicles which are effective and dependable in conquering physiological and
cellular obstacles, and exceedingly target-specific. Gene therapy of gliomas could be improved by using the approach of CTX-conjugated NPs.

Huang et al. designed a glioma-targeted gene delivery system [74]. A major vector was constructed by polyamidoamine (PAMAM), a nanoscopic high-branching dendrimer. Through bio-functional PEG, PAMAM was conjugated to CTX to produce PAMAM-PEG-CTX. The modification of CTX could prominently promote the cellular uptake of the DNA-loaded NPs and vectors in C6 cells. PAMAM-PEG-CTX/DNA NPs were more widely distributed in the brain than PAMAM-PEG/DNA NPs and PAMAM/DNA NPs in vivo. In addition, the gene expression of PAMAM-PEG-CTX/DNA NPs in glioma was broader and higher than that of PEG-modified and unmodified counterparts. The median survival time of CTX-modified group was remarkably longer than that in other groups. The results showed that PAMAM-PEG-CTX/DNA NPs can be used as a
promising non-viral gene delivery system for gene therapy of glioma.

Kievit et al. attached CTX to an iron oxide nanoparticle core using a short PEG linker [75]. Green fluorescent protein (GFP) encoding DNA was then bound to the nanoparticle. A copolymer of chitosan and PEI were coated to the nanoparticles to yield NP-PEG-PEI-GFP-CTX. A control nanoparticle, NP-PEG-PEI-GFP, was also prepared. The C6 tumor bearing mice were intravenously injected with the DNA bound nanoparticles. The use of CTX targeted nanoparticles loaded with DNA specifically enhanced glioma cell uptake. CTX was found to enhance nanoparticle uptake by the tumor cells as proved by the increase of GFP expression, while the targeting ligand did not affect the accumulation and biodistribution of nanovector in the tumor site. The results showed that specific uptake of nanovectors into glioma cells could be improved by exposing a higher percentage of target cells to the delivered payload.

Although PEI nanoparticles have been recognized as effective gene delivery systems, the non-selective delivery and inherent toxicity of the material are the major problems for clinical translation. Veiseh et al. presented a non-viral nanovector P-PEG-AF-CTX comprising a PEI polymer, PEG, fluorescent dye AF, and CTX, which could be used to bind a series of tumor cells specifically for genetic treatment [38]. Since the nanovector can be specifically delivered to tumor cells, the toxicity of nanovector to healthy cells is minimized. The nanovector exhibited high levels of gene transfection efficiency and targeting specificity in both DAOY medulloblastoma and C6 glioma cells (Figure 4). Importantly, the nanovector with the CTX may serve as a broadly applicable gene carrier for a variety of cancer types.

Ribonucleic acid interference (RNAi) is a rapidly developing technology that has been applied in gene therapy of cancer. The absence of site-targeting delivers that can effectively carry short interfering RNA (siRNA) to tumor cells is one of major challenges for translating this technology into the clinic [76]. In 2010, NP-siRNA-CTX, the first siRNA nanovector, was designed for glioma-targeted imaging and therapy [77]. The nanovector was constructed with PEI, PEG-grafted chitosan, and a superparamagnetic iron oxide nanoparticle core. The construct was also coated with CTX and siRNA. The data suggested that this CTX functionalized nanovector can deliver RNAi therapeutics to tumor cells. Later on, the same group developed a multifunctional nanosystem (NP-PEib-siRNA-CTX) constructed with CTX, siRNA, and highly amine blocked PEI (PEib). NP-PEib-siRNA-CTX presented both gene silencing effects and significant cytotoxic at acidic conditions in C6 cells, but not at physiological conditions [78]. The CTX component of NP-PEib-siRNA-CTX improved the nanovector uptake by cancer cells. The size (63 nm) of NP-PEib-siRNA-CTX is suitable for this nanovector to be accumulated in tumor tissues through the enhanced permeability and retention effect. NP-PEib-siRNA-CTX can not only maintain enough magnetism for MR imaging, but also offer an imaging tool to monitor the delivery of therapeutic payload in a real time [79].

**CTX-functionalized nanoparticles**

Nanoparticles have been emerged as contrast agents, drug delivery vehicles, and multifunctional devices for patient care. Development of multifunctional nanoparticles for targeting cancer cells has become a focus of research in the past few years [80]. Tumor-specific delivery, stability and biocompatibility are technological difficulties in the progress of developing ideal nanoparticle-based therapeutic agents [81]. At present, the main approaches are focused on delivering chemotherapeutic agents to induce apoptosis or DNA/siRNA by changing oncogene expression.

Veiseh et al. reported a nanoparticle system consisted of an iron oxide nanoparticle core, CTX and an amine-functionalized PEG silane [26]. They showed that the nanoparticle exhibited significantly increased cellular uptake and an invasion inhibition rate of 98% compared with unbound CTX (45%). Their studies demonstrated that the nanoparticle functionalized by CTX could reduce the activity of MMP-2 and increase internalization of lipid rafts that contain volume-regulating ion channels and membrane-expressed MMP-2 via receptor-mediated endocytosis, leading to the enhancement of invasion inhibition (Figure 5). Since upregulation of MMP-2 activity has also been observed in cancers of the skin, colon, breast, prostate, and lung, this nanovector system can be potentially applied for therapy of a broad spectrum of tumors.
A multifunctional nanoparticle system which comprises CTX, an iron oxide nanoparticle core, and methotrexate (MTX, a conventional chemotherapeutic agent) was presented by Sun et al [82]. The NP-MTX-CTX system can serve as a diagnostic and therapeutic tumor targeted nanovector. In this nanosystem, the functional ligands such as CTX and MTX were covalently attached to the iron oxide core through a PEG layer which is a biocompatible linking and coating molecule. The result indicated that the nanoparticle was able to carry MTX specifically to tumor cells, including glioma and medulloblastoma. Compared with NP-MTX, NP-MTX-CTX was more effective in inducing cytotoxicity in tumor cells, likely due to the increased uptake. At 24 h, the cell viability for NP-MTX-CTX reached a minimum at 25.6% and maintained this level for additional 24 h, while cells treated with NP-MTX began to recover with increasing proliferation reaching normal untreated levels by 72 h. NP-MTX-CTX was also able to retain in the tumor tissue more than 14 days, and deliver combined chemotherapeutic molecules specifically to tumor cells.

Multifunctional nanovectors formed by polymeric nanoparticles (PNPs) were synthesized, which contain two cytotoxic elements - the silver nanoparticles and drug alisertib. PNPs are optimal nanocarriers for targeted drug delivery due to their small size and ability to entrap efficaciously drug molecules. The poly(lactic-co-glycolic acid) (PLGA)-block-PEG-carboxylic acid

Figure 5. (A) NPC binding to lipid rafts of glioma cells containing MMP-2 and select ion channels. C6 cells incubated with AF680 fluorescently labeled NPC, NP or CTX and analyzed by (B) Z-stacked 2-D projections and (C) 3-D reconstructions (DAPI nuclear stain in blue, WGA 594 membrane stain in green, and AF680 in red). (scale bar: 10 μm). Reprinted with the permission of the Journal of Small, Veiseh et al., 2009.
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

Table 3. Representative BmK CT bioconjugates in the applications of glioma diagnosis and treatment

<table>
<thead>
<tr>
<th>Type</th>
<th>Cell Line</th>
<th>Study</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BmK CT</td>
<td>U251, BEL7404,</td>
<td>In vitro &amp; In vivo</td>
<td>[89]</td>
</tr>
<tr>
<td>BmK CT</td>
<td>CHOC400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>131I-BmK CT</td>
<td>SHG-44</td>
<td>In vitro &amp; In vivo</td>
<td>[91]</td>
</tr>
<tr>
<td>BmK CT</td>
<td>C6</td>
<td>In vitro</td>
<td>[92]</td>
</tr>
<tr>
<td>Adenovirus-BmK CT</td>
<td>C6</td>
<td>In vitro &amp; In vivo</td>
<td>[96]</td>
</tr>
<tr>
<td>pEGFP-N1-BmK CT</td>
<td>C6</td>
<td>In vitro</td>
<td>[97]</td>
</tr>
<tr>
<td>Imaging and Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>131I-BmK CT, Cy5.5-BmK CT</td>
<td>C6</td>
<td>In vivo</td>
<td>[90]</td>
</tr>
<tr>
<td>FND-BmK CT</td>
<td>C6</td>
<td>In vitro</td>
<td>[98]</td>
</tr>
</tbody>
</table>

Notes: BEL7404, hepatocellular carcinoma cell line; CHOC400, Chinese hamster ovary cell line; SHG-44, human glioma cell line.

(PLGA-b-PEG) copolymer is becoming one of the most promising system for drug loading and in vivo drug delivery applications. Locatelli et al. reported an PNP, containing the drug alisertib (Ali), a selective aurora A kinase inhibitor, lipophilic silver (Ag)-loaded PNPs derived from the PLGA-b-PEG-COOH block copolymer and CTX, named Ag/Ali@PNPs-CTX [57]. The synergistic and individual property of these two cytotoxic molecules against GBM was evaluated both in vivo and in vitro. The result suggested that tumor reduction was achievable while using Ag/Ali@PNPs-CTX.

Application of BmK CT bioconjugates for gliomas imaging and therapy

CTX-like peptides derived from the venom of various scorpion species generally shares sequence homology with CTX. Buthus martensii Karsch chlorotoxin (BmK CT) which was purified from the venom of the Chinese scorpion, is the most important CTX-like peptide. The representative BmK CT bioconjugates are summarized in Table 3.

Source and chemical structure of BmK CT

The Buthus martensii Karsch (BmK) is a kind of East-Asian scorpion extensively distributed in northwestern China, Korea, and Mongolia. A full-length cDNA sequence encoding BmK CT was purified from a cDNA library of the Chinese BmK venom glands. The encoding peptide of BmK CT has 59 amino acid residues in length which included a mature toxin of 35 residues with four disulfide bridges and a signal peptide of 24 residues. There are 68% similarities between BmK CT and CTX in sequence [83, 84].

Purification of BmK CT

Through modifying BmK CT gene sequence based on the codon usage in Escherichia coli (E. Coli) and subcloning it into an expression vector pExSecI, recombinant BmK CT was successfully purified and expressed in E. Coli [85]. Plenty expression of a soluble and functional modality of BmK CT was thus obtained, which could be applied for the pharmaceutical function of this neurotoxin.

Putative mechanisms of BmK CT

The polypeptidy toxins purified from BmK venom can specifically interfere with a number of ion channels and change their functional features [86]. A study was conducted to determine the potential receptors of this CTX-like peptide in human glioma cell by using polyclonal antibodies to the purified protein raised in rats. Pull-down assay and overlay assay revealed that this toxin specifically binds to two proteins in the glioma cells with molecular weights of about 35 and 80 kDa. These proteins may be considered as candidate receptors or alternative cellular molecules interacting with BmK CT [87].

Electrostatic effects play an important role in the interaction between the small basic peptides of the scorpion venom and the ion channels. The inhibition of BmK CT on MMP-2 activity has been studied using computational methods. Fu et al. proposed a model to elaborate the structural mechanism of this CTX-like peptide on glioma invation (Figure 6) [88]. In this study, the genes encoding BmK CT^{R14K15AA}, BmK CT^{R17A}, BmK CT^{R25A}, and BmK CT^{R35A} were amplified by PCR. The results from gelatin zymography assay showed that BmK CT and mutant forms could decrease glioma cells...
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

Figure 6. Three dimensional structures and electrostatic surfaces of MMP-2 catalytic domain (A), BmK CT (B) and mutants (C-F). Electrostatic surfaces are calculated by the program DeepView V.3.7. Different color codes are -1.8 kT/e (Red) and 1.8 kT/e (Blue) where k is the Boltzmann constant, T is the temperature in Kelvin, and e is the charge of the electron. Positively charged residues are shown in blue and negatively charged in red. The basic amino acid residues of BmK CT and site-directed mutagenesis are shown in yellow. Reprinted with the permission of the Journal of Biotechnology Letters, Fu et al., 2011.

metastasis rate via MMP-2. The inhibitory effect of BmK CT, BmK CT^{K25A} and BmK CT^{R35A} was stronger than that of BmK CT^{R14K15AA} and BmK CT^{R17A}. The electrostatic surfaces of both catalytic domain of MMP-2 and BmK CT (mutants and wild type) were counted to determine the structure-function. The results demonstrated that the catalytic domains in BmK CT^{R17A}, MMP-2 and BmK CT^{R14K15AA}-MMP-2 complexes were less stable than those of BmK CT^{R35A}, MMP-2, BmK CT^{K25A}-MMP-2 and BmK CT-MMP-2 complexes. The molecular dynamics simulation showed that R^{14,17} and K^{15} residues may be three active residues of BmK CT interacting with the catalytic domain of MMP-2, which was proved by the in vitro experimental measurements [88].

Potential of BmK CT in glioma imaging and therapy

Wang et al. reported that BmK scorpion venom can induce U251-MG cell death at a dose of 10 mg/ml, but no effect on human hepatocellular carcinoma cells and Chinese hamster ovary cells was observed [89]. In a mouse U251-MG xenograft model, BmK venom showed remarkable inhibition of the tumor proliferation. Recent studies also revealed that both CTX and BmK CT could inhibit glioma cell proliferation, and Cy5.5 conjugated BmK CT is target-specific for gliomas in a rat xenograft model [90].

BmK CT has been characterized by in vivo and in vitro studies [91]. The cell proliferation assay revealed that BmK CT inhibits the glioma cell growth (SHG-44, human glioma cells) in a dose-dependent pattern with an IC_{50} value of 0.28 µM, while the IC_{50} value of BmK CT for normal astrocytes increased to 8 µM under the same conditions. The whole-cell patch-clamp recording showed that BmK CT could inhibit chloride current in SHG-44 in a voltage-dependent manner. The inhibition rates of BmK CT on I_{Cl} were determined to be 17.64 ± 3.06% and 55.86 ± 2.83% at the concentrations of 0.07 and 0.14 µM, respectively. Mice were also treated with rBmK CTa, a gene encoding chlorotoxin-like peptide from the scorpion, Buthus martensii Karsch. Histological analysis of rBmK CTa treat-
ed mice revealed that this toxin was distributed in brain, cardiac muscle, and leg muscle. These results suggested that rBmK CTa may have potential in the treatment of human gliomas.

In addition, BmK CT was labeled with $^{131}$I using the Bolton–Hunter method with the overall yield of 34.5% [92]. MTT assay demonstrated that both BmK CT and $^{131}$I-BmK CT could inhibit C6 growth. The ability of $^{131}$I-BmK CT to inhibit cell growth is superior to that of BmK CT. Whereas BmK CT could block the C6 glioma cell cycle in the G0/G1 stage, $^{131}$I-BmK CT is capable to block the cell cycle in the S stage at a radioactivity concentration of 50 µCi/mL. Hence, $^{131}$I-BmK CT may be useful as a glioma-targeted therapy agent better than BmK CT, while $^{131}$I-BmK CT may also be used for SPECT imaging.

**BmK CT and lithium chloride (LiCl)**

High-grade gliomas (HGGs) are rapidly progressive brain tumors with a low survival rate due to the devastating invasion and high recurrence rate. It is very difficult to completely remove the tumor tissue by surgical method [2]. Although specific pathophysiological mechanisms underlying resistance of HGGs to chemotherapy are still unclear, recent studies have revealed the importance of glycogen synthase kinase-3 (GSK-3) in inhibiting glioma cell progression and invasion. GSK-3 inhibition could result in glioma cell apoptosis by interfering with c-MYC activation and intracellular glucose metabolism [93]. Lithium as an inhibitor of GSK-3 has been applied in clinical therapy of bipolar disorder for several decades. A recent study showed that a high concentration of lithium is required to significantly inhibit the migration ability of most glioma cell lines [94]. However, lithium is often toxic at high concentrations, limiting its applicability as a therapeutic agent against gliomas.

Aiming to find out an approach to reduce the concentration of lithium at which the inhibitory effects remain significant, Fu et al. have studied whether the simultaneous administration of BmK CT and LiCl could be potentially beneficial for the treatment of HGGs [95]. In this study, the combination of BmK CT and LiCl could significantly inhibit the proliferation, invasion, and migration of C6 glioma cells, suggesting that BmK CT could reduce the “toxic” effects of lithium by preventing the metastatic spread of glioma cells to a certain extent. The results demonstrated that BmK CT could inhibit the lithium and the collagen type I-induced activation and overexpression of pro-MMP-2. Additionally, the combination treatment changed β-catenin localization patterns at the migration edge, disrupted cell-cell contacts, and caused the morphological alteration of C6 glioma cells.
Gene therapy has been served as a new strategy for the treatment of gliomas. Adenovirus-mediated delivery of the conditional cytotoxic gene was proved to be an adjuvant gene therapeutic method of gliomas. A recombinant adenoviral system was developed through a double-recombination product between a shuttle vector pShuttleIREs-hrGFP-2 carrying the BmK CT gene and a co-transformed adenoviral backbone plasmid vector, pAdEasy-1 [96]. This delivery system specifically targeted BmK CT to rat C6 glioma cells. The delivered BmK CT interacted with the MMP-2 and/or pro-MMP-2 in the glioma cells, which avoided immunologic rejection and degradation of BmK CT protein. The BmK CT mediated by adenovirus showed a high activity in preventing glioma cells from growing and invading, thereby proposing that this recombinant adenovirus is an effective approach for the treatment of glioblastoma. A type of green fluorescent protein encoded by pEGFP-N1 has been applied for brighter fluorescence and higher expression in mammalian cells. Recently, Fu et al. constructed a recombinant plasmid pEGFP-N1-BmK CT ([Figure 7A] [97]. The results showed that pEGFP-N1 mediated BmK CT expression exhibited a high activity in inhibiting cell migration via MMP-2 ([Figure 7B]).

**BmK CT-based nanoparticles**

As optical imaging probes, fluorescent nanodiamonds (FND) have gained considerable attention. BmK CT-conjugated with FND was proposed as a new class of glioma-specific nanoparticles [98]. The confocal fluorescence assay confirmed receptor-mediated uptake of FND-BmK CT bioconjugates into rat C6 glioma cells by direct tumor visualization. The in vitro wound healing assay showed that FND-BmK CT had high inhibition rate during the migration of rat C6 glioma cells. Therefore, glioma-specific multifunctional nanoparticles (FND-BmK CT) might be useful for the development of more effective therapeutic agents for clinical treatment of gliomas.

**Conclusions and perspectives**

CTX and CTX-like peptide (BmK CT) represent novel and exciting platforms for glioma imaging and therapy due to the major advantages as follows: 1) small and condensed structure; 2) feasibility of artificial synthesis and the readily modified chemical structure with a tyrosine residue conjugating iodine or other molecules covalently; 3) rapid diffusion into tumor parenchymas and ability to penetrate the BBB; 4) slow elimination through the metabolism with a longer imaging time due to intracellular binding with glioma cells; 5) derivation from an invertebrate, being not rejected by human tissue, the absence of intimate toxicity without binding to normal tissue and cells; 6) antitumor activity in inhibiting tumor invasion and metastasis; and 7) antiangiogenic effects.

Currently, investigators have conjugated CTX and BmK CT with radioactive iodine isotopes, fluorescent molecules, gene (DNA and RNA) and nanoparticles, and subsequently localized these bioconjugants with the imaging tools, offering a unique and specific approach with theranostic potential for gliomas. Although the recent studies of CTX-based bioconjugates are promising, the development of an effective approach to treat gliomas remains a challenge due to high malignance of gliomas. Additionally, the in vivo toxicity of various bioconjugates should be monitored in a long term. With recent developments in nanotechnology, we can envision that CTX- or BmK CT-conjugated nanomedicine may have a great potential for diagnosis and treatment of gliomas.

**Acknowledgements**

This work was supported by the USC Department of Radiology, National Natural Science Foundation of China (No. 81171368, 812111366, and 81301245), and Japan Society for the Promotion of Science Fellowship (No. S-11109).

**Disclosure of conflict of interest**

The authors declare that they have no conflict of interest.

**Abbreviations**

CTX, chlorotoxin; BmK CT, Buthus martensii Karsch Chlorotoxin; GBM, glioblastoma multiforme; MMP-2, matrix metalloproteinase-2; ECM, extracellular matrix; E. Coli, Escherichia coli.; GCC, glioma-specific chloride channel; CIC, chloride ion channels; MT1-MMP, membrane type-1 MMP; CLIC1, chloride intracellular...
Theranostic chlorotoxin agents for diagnosis and treatment of gliomas

channel 1; CFTR, cystic fibrosis transmembrane conductance regulator; GST, glutathione transferase; AaCtx, Androctonus australis chlorotoxin; BBB, blood-brain barrier; NPs, nanoparticles; NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid; PEG, polyethylene glycol; AF, Alexa Fluor 647; PEl, polyethyleneimine; LS, liposomes; DOX, doxorubicin; NO, nitric oxide; asOs, antisense oligonucleotides; SNALPs, stable nucleic acid lipid particles; PNPs, polymeric nanoparticles; PLGA-b-PEG, poly(lactic-co-glycolic acid) (PLGA)-block-PEG-carboxylic acid; Ali, ailsertib; BCNU, carmustine; MGMT, O6-Methylguanine-DNA Methyltransferase; TMZ, temozolomide; PAMAM, polyamidoamine; GFP, green fluorescent protein; siRNA, short interfering RNA; RNAi, ribonucleic acid interference; MTX, methotrexate; Pdots, polymer dots; Qdots, quantum dots; PBdots, polymer-blend dots; RGD, arginine-glycine-aspartic acid; MRS, magnetic resonance spectroscopy; MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography; PET, positron emission computed tomography; NIRF, near-infrared fluorescence; Gd-DTPA, Gadolinium ion-diethylene triaminopentaacetic acid; ICG, indocyanine green; CCD, charge-coupled device; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHDF, normal human dermal fibroblasts; HGGs, high-grade gliomas; GSK-3, glycogen synthase kinase-3; FND, fluorescent nanodiamonds; rBmK CTa, a gene encoding chlorotoxin-like peptide from the scorpion, Buthus martensii Karsch.

Address correspondence to: Jinhua Zhao, Department of Nuclear Medicine, The First People’s Hospital, Shanghai Jiaotong University, 85 Wujin Road, Shanghai 200080, P.R. China. E-mail: zhaojinhua1963@126.com; Kai Chen, Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC103, Los Angeles, CA 90033, USA. E-mail: chenkai@med.usc.edu

References


Theranostic chlorotoxin agents for diagnosis and treatment of gliomas


Theranostic chlorotoxin agents for diagnosis and treatment of gliomas


[52] Minchenko DO, Kharkova AP, Hubenia OV and Minchenko OH. Insulin receptor, IRS1, IRS2, INSIG1, INSIG2, RRAD, and BAIAP2 gene expressions in glioma U87 cells with ERN1 loss of function: effect of hypoxia and glutamine or glucose deprivation. Endocr Regul 2013; 47: 15-26.


Theranostic chlorotoxin agents for diagnosis and treatment of gliomas


[83] Zeng XC, Li WX, Zhu SY, Peng F, Zhu ZH, Wu KL and Yang FH. Cloning and characterization of

a cDNA sequence encoding the precursor of a chlorotoxin-like peptide from the Chinese scorpion Buthus martensi Karsch. Toxicon 2000; 38: 1009-1014.


